PA
ENSC icon

Perceptive Advisors’s Ensysce Biosciences ENSC Stock Holding History

Perceptive Advisors’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.7K Hold
86,666
– – ﹤0.01% 93
2025
Q4 		$79.7K Hold
86,666
– – ﹤0.01% 115
2025
Q3 		$205K Hold
86,666
– – 0.01% 90
2025
Q2 		$193K Hold
86,666
– – 0.01% 83
2025
Q1 		$222K Hold
86,666
– – 0.01% 84
2024
Q4 		$705K Buy
+86,666
New +$597K 0.02% 94

Other funds holding ENSC

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Perceptive Advisors's ENSC Position: Q1 2026 in Review

Perceptive Advisors held its Ensysce Biosciences (ENSC) position steady in Q1 2026 at 86,666 shares worth $46.7K. The position accounts for ﹤0.01% of the portfolio, ranked #93.

Perceptive Advisors first reported a position in ENSC in Q4 2024 and has held it in 6 quarters since. The position peaked at $705K in Q4 2024. 15 funds tracked by Wall St. Rank hold ENSC as of Q1 2026.

  • Perceptive Advisors held 86,666 shares of Ensysce Biosciences worth $46.7K as of Q1 2026.
  • Perceptive Advisors left its Ensysce Biosciences share count unchanged in Q1 2026.
  • Ensysce Biosciences made up ﹤0.01% of Perceptive Advisors's portfolio in Q1 2026, its #93 holding.
  • Perceptive Advisors first reported a position in Ensysce Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Perceptive Advisors's Ensysce Biosciences position peaked at $705K in Q4 2024.
  • 15 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.